Solute carrier family 15 member 5 (SLC15A5)

Solute carrier family 15 member 5 (SLC15A5) is a predicted member of the SLC15 family of proton-coupled oligopeptide transporters, which generally transport di- and tripeptides and certain amino acids across biological membranes. However, SLC15A5 is an orphan transporter that has not been functionally characterized, and most of its biological activities, substrates, and disease associations remain unreported. SLC15A5 is reported to be predominantly expressed in the brain, based on mRNA evidence, but there are no data detailing its specific substrates, functions, or therapeutic relevance in the current literature. It is distinct from other better-characterized SLC15 family members (such as SLC15A1/PEPT1, SLC15A2/PEPT2, SLC15A3/PHT2, and SLC15A4/PHT1), which have well-defined physiological and pathological roles[3][5][6]. Notes: - SLC15A5 is not currently considered a known drug target or established therapeutic target because of a lack of functional characterization or evidence of direct involvement in disease pathophysiology[3][5]. - The alternative names provided (e.g., Peptide/histidine transporter ENSP00000340402) are predicted but have not been validated by functional data. - If you are referring to the better-characterized SLC15A4 (PHT1, peptide/histidine transporter 1), it is a recognized immune system transporter and emerging drug target in inflammation and autoimmunity, but this does not apply to SLC15A5. Summary: There is currently insufficient information to classify SLC15A5 as a functional or therapeutic target. Most literature references SLC15A5 only as a predicted gene/product, with no established functional or disease role or known interacting compounds[3][5].

Other names

SLC15A5Solute carrier family 15 member 5